ScreenerHero

DMACDiaMedica Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · diamedica.com
6.520USD-4.26%Mkt Cap: 351.60M $P/E: —

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinan…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap351.60M $
Enterprise Value308.28M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-32.77M $
Revenue/Share—
Last Price6.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.07
PEG—
EV/EBITDA-7.87
EV/Revenue—
P/S—
P/B9.17
EPS (TTM)-0.69
EPS (Forward)-0.81
52W Range
5.14026% of range10.42
52W High10.42 USD
52W Low5.140 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.39%
ROA-53.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.06M $
CapEx (TTM)40.00K $
FCF Margin—
FCF Yield-5.02%
Net Debt-43.32M $
Net Debt/EBITDA1.11
Balance Sheet
Debt/Equity0.00
Current Ratio6.72
Quick Ratio6.63
Book Value/Sh0.7110 USD
Cash/Share0.8070 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 15, 2018
Splits
Last Split1:20
Split DateNov 15, 2018
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.50 USD
Upside (mean)+137.7%
Target Range11.00 USD – 25.00 USD
$11.00+137.7% to mean$25.00
# Analysts4
Ownership
Shares Out.53.93M
Float25.30M
Insiders27.83%
Institutions40.91%
Short Interest
Short Ratio23.7d
Short % Float14.38%
Short % Out.9.65%
Shares Short5.20M
Short (prev mo.)5.21M
Technical
SMA 506.739 (-3.2%)
SMA 2007.186 (-9.3%)
Beta0.97
S&P 52W Chg18.16%
Avg Vol (30d)159.95K
Avg Vol (10d)138.00K
Technical Indicators
RSI (14)44.4
MACD-0.0333
MACD Signal-0.0231
MACD Hist.-0.0101
BB Upper6.966 USD
BB Middle6.654 USD
BB Lower6.343 USD
BB Width9.36%
ATR (14)0.3446 USD
Vol Ratio (20d)0.50x